GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2015 Financial Results and Operational Progress

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Dec 07, 2015

- Three Phase 3 Epidiolex clinical trials fully recruited above target sample size – on track for initial data in Q1 2016 -

- Significant clinical activity in multiple cannabinoid pipeline programs -

- Conference Call Today at 4:30 p.m. EST, 9:30 p.m. GMT -

London, UK, 7 Dec 2015: GW Pharmaceuticals plc (NASDAQ: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results for the fourth quarter and twelve months ended 30 September 2015.

Recent News